{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:03:55Z","timestamp":1790996635511,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.parkreldis.2013.07.009","type":"journal-article","created":{"date-parts":[[2013,8,6]],"date-time":"2013-08-06T18:16:37Z","timestamp":1375812997000},"page":"1022-1026","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: A multicenter, double-blind, randomized, placebo-controlled study"],"prefix":"10.1016","volume":"19","author":[{"given":"Zhenxin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengdi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenfu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baorong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiumin","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongxuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2013.07.009_bib1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1212\/WNL.49.2.393","article-title":"Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group","volume":"49","author":"Adler","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2013.07.009_bib2","first-page":"101","article-title":"A\u00a0placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease","volume":"21","author":"Brooks","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.parkreldis.2013.07.009_bib3","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1212\/WNL.51.4.1057","article-title":"A\u00a0multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group","volume":"51","author":"Lieberman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2013.07.009_bib4","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1212\/WNL.53.2.364","article-title":"A\u00a03-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group","volume":"53","author":"Korczyn","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2013.07.009_bib5","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s007020200040","article-title":"A\u00a0six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa","volume":"109","author":"Brunt","year":"2002","journal-title":"J\u00a0Neural Transm"},{"key":"10.1016\/j.parkreldis.2013.07.009_bib6","first-page":"95","article-title":"Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease","volume":"37","author":"Lieberman","year":"1983","journal-title":"Adv Neurol"},{"key":"10.1016\/j.parkreldis.2013.07.009_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1185\/03007998609111089","article-title":"The safety of bromocriptine in long-term use: a review of the literature","volume":"10","author":"Weil","year":"1986","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.parkreldis.2013.07.009_bib8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/00003495-199039030-00009","article-title":"Pergolide: a review of its pharmacological properties and therapeutic potential in Parkinson's disease","volume":"39","author":"Langtry","year":"1990","journal-title":"Drugs"},{"key":"10.1016\/j.parkreldis.2013.07.009_bib9","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1212\/WNL.35.5.749","article-title":"Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide","volume":"35","author":"Goetz","year":"1985","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2013.07.009_bib10","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1212\/01.wnl.0000258660.74391.c1","article-title":"Ropinirole 24-hour prolonged release: randomized, controlled study in Parkinson disease","volume":"68","author":"Pahwa","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2013.07.009_bib11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/clpt.2008.141","article-title":"The role of ethnicity in variability in response to drugs; focus on clinical pharmacology studies","volume":"84","author":"Yasuda","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.parkreldis.2013.07.009_bib12","unstructured":"Liu H, Jian J, Want H, Chen X, Liu T, Cao H, et\u00a0al. A single and multiple dose study to investigate the pharmacokinetics of a prolonged release formulation of ropinirole in healthy Chinese subjects. Clin Pharmacol Drug Dev, in press."},{"key":"10.1016\/j.parkreldis.2013.07.009_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00002826-200003000-00003","article-title":"A\u00a0home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia","volume":"23","author":"Hauser","year":"2000","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.parkreldis.2013.07.009_bib14","first-page":"153","volume":"vol. 2","year":"1987"},{"key":"10.1016\/j.parkreldis.2013.07.009_bib15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A\u00a0rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.parkreldis.2013.07.009_bib16","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/jnnp.73.6.629","article-title":"The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease","volume":"73","author":"Chaudhuri","year":"2002","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.parkreldis.2013.07.009_bib17","first-page":"S10","article-title":"PDDQ-39: a review of the development, validation and application of a PD quality of life questionnaire and its associated measures","volume":"245","author":"Peto","year":"1998","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.parkreldis.2013.07.009_bib18","series-title":"ECDEU assessment manual for psychopharmacology, revised","first-page":"217","article-title":"Clinical global impression","author":"Guy","year":"1976"},{"key":"10.1016\/j.parkreldis.2013.07.009_bib19","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0006-3223(01)01079-4","article-title":"Double blind naltrexone and placebo comparison study in the treatment of pathological gambling","volume":"49","author":"Kim","year":"2001","journal-title":"Biol Psychiatry"},{"issue":"11 Suppl.\u00a04","key":"10.1016\/j.parkreldis.2013.07.009_bib20","first-page":"S42","article-title":"Benefits of COMT inhibitors in levodopa-treated parkinsonian patients results of clinical trials","volume":"55","author":"Kieburtz","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2013.07.009_bib21","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ana.410420511","article-title":"Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients","volume":"42","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.parkreldis.2013.07.009_bib22","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1212\/WNL.51.5.1309","article-title":"Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group","volume":"51","author":"Rinne","year":"1998","journal-title":"Neurology"}],"updated-by":[{"DOI":"10.1016\/j.parkreldis.2014.03.025","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000}}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802013002630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802013002630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:13:38Z","timestamp":1761178418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802013002630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S1353802013002630"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2013.07.009","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: A multicenter, double-blind, randomized, placebo-controlled study","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2013.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}